tag:blogger.com,1999:blog-75916062026-07-24T01:05:37.228-05:00Overcoming HIVRoaming the USA and the globe for emerging and cutting edge HIV and health information usually not found in a doctor's office or in publications. A blog of Program for Wellness Restoration: www.powerusa.orgAnonymoushttp://www.blogger.com/profile/07508096149475469122noreply@blogger.comBlogger555125tag:blogger.com,1999:blog-7591606.post-61043006873491609432016-04-08T10:38:00.003-05:002016-04-08T10:38:32.734-05:00Life Expectancy Rising in HIV Group Over 50, But Still Lags General Population
Estimated median survival in the HIV group rose from 11.8 years in 1996-1999 to 17.8 years in 2000-2005 and to 22.5 years in 2006-2014. Median survival in general population controls was 30.2 years across all three periods. Mortality rate ratio comparing HIV-positive people with controls was highest among 50- to 55-year-olds (3.8) and declined in each older age group. But in the oldest age groupAnonymoushttp://www.blogger.com/profile/07508096149475469122noreply@blogger.comtag:blogger.com,1999:blog-7591606.post-35971479674471175042016-04-08T10:36:00.005-05:002016-04-08T10:36:50.134-05:00New HIV Drug Has Potential for Weekly or Once-Yearly Dosing
One of the surprises at CROI 2016 was the first virological data from a new highly potent NRTI that in a slow-release formulation has the potential for annual dosing and that is undergoing research as both treatment and PrEP.In an oral late-breaker, Jay Grobler from Merck presented results from a dose-ranging study in macaques to develop a model for phase 1 studies with MK-8591 (EFdA).1Baseline Anonymoushttp://www.blogger.com/profile/07508096149475469122noreply@blogger.comtag:blogger.com,1999:blog-7591606.post-17133690593352996462016-04-08T10:25:00.002-05:002016-04-08T10:25:36.017-05:00Switching HIV+ Patients From Stribld to Genvoya Improved Proteinuria but Not eGFR
CROI 2016 Conference
Abstract Number:
795
Safety of Tenofovir Alafenamide in Renal Impairment
Author(s):
Anton Pozniak2, Jose R Arribas3, Samir K. Gupta4, Frank A. Post5, Anchalee Avihingsanon6, Gordon Crofoot7, Kenneth A. Lichtenstein8, Moti Ramgopal9, Ploenchan Chetchotisakd10, Marshall W. Fordyce11 Clinical Research, Gilead Sciences Inc, Foster City, CA, Anonymoushttp://www.blogger.com/profile/07508096149475469122noreply@blogger.comtag:blogger.com,1999:blog-7591606.post-37103333997388264142016-04-08T09:56:00.001-05:002016-04-08T09:56:44.618-05:00HIV Mutates Around Promising Gene Editing Technology (CRISPR-CAS 9)
HIV can defeat efforts to cripple it with CRISPR gene-editing technology, researchers say. And the very act of editing — involving snipping at the virus’s genome — may introduce mutations that help it to resist attack.
At least half a dozen papers over the past three years have explored using the popular CRISPR–Cas9 gene editing technique to combat HIV, but the latest finding, described in a Anonymoushttp://www.blogger.com/profile/07508096149475469122noreply@blogger.comtag:blogger.com,1999:blog-7591606.post-34678028879845776742015-11-30T12:14:00.001-06:002015-11-30T12:14:31.920-06:00HIV-related wasting can have long-term consequences
HIV-related wasting can have long-term consequences
People who suffered wasting in the past more vulnerable to frailty in later life
Michael Carter
Published: 30 November 2015
HIV-associated wasting can have a long-term impact on physical function and quality of life, according to research from the United States published in the online edition of AIDS. The research was Anonymoushttp://www.blogger.com/profile/07508096149475469122noreply@blogger.comtag:blogger.com,1999:blog-7591606.post-90353557461786901982015-10-28T11:50:00.003-05:002016-04-08T09:41:50.908-05:00HPV and HIV: What You Need to Know About Anal Cancer (Video)Men who have anal sex with men (MSM) are more likely to get anal HPVthan men who only have sex with women. Researchers estimate that the prevalence of anal HPV among men who only have sex with women is around 15% while anal HPV prevalence for MSM is around 60%. If you add HIV into the mix, infection risk goes up still—one study published by HIV Medicine found that 77% of MSM Anonymoushttp://www.blogger.com/profile/07508096149475469122noreply@blogger.comtag:blogger.com,1999:blog-7591606.post-86962905939196482422015-09-12T12:13:00.003-05:002015-09-12T12:13:30.081-05:00Best Posts on Aging with HIV from TheBody.com This Week
Forum on Aging With HIV: H. Pylori and HIV: What Do I Need to Know? (Editor's Pick)
Forum on Aging With HIV: H. Pylori and HIV: What Do I ...
I am very familiar with H. Pylori. I was diagnosed with it using a urea breath test 2 years ago when I was diagnosed with lymphoma on the stomach wall. This was cau...
View on Anonymoushttp://www.blogger.com/profile/07508096149475469122noreply@blogger.comtag:blogger.com,1999:blog-7591606.post-26479674567865258582015-09-10T09:10:00.000-05:002015-09-10T09:36:30.908-05:00Two New HIV Studies Give Access to Research Medications to People with Multi-Drug Resistance
By Nelson Vergel. SalvageTherapies.org
No one can deny that many patients can now suppress their HIV with effective antiretrovirals (ARVs) that cause fewer side effects. However, a vulnerable and often forgotten minority of people are still struggling with multi-drug resistant HIV (MDR-HIV) while they anxiously wait for access to lifesaving ARVs that would finally control their Anonymoushttp://www.blogger.com/profile/07508096149475469122noreply@blogger.comtag:blogger.com,1999:blog-7591606.post-53292367633916648292015-09-10T00:05:00.004-05:002015-09-10T00:05:57.904-05:00Webcast : Beyond the Berlin Patient- How Researchers Are Now Trying to Cure More HIV+ People
Webcast : Beyond the Berlin Patient- How Researchers Are
Now Trying to Cure More HIV+ People
By Nelson Vergel
We all read
headlines almost weekly about the latest HIV cure. After years of being exposed to these
inflamed news reports, we may get desensitized to the fact that there is
actually progress being made in that field.
Ever since Timothy Brown was proven to be Anonymoushttp://www.blogger.com/profile/07508096149475469122noreply@blogger.comtag:blogger.com,1999:blog-7591606.post-77128620222481119562015-08-28T12:24:00.001-05:002015-08-28T12:26:31.137-05:00Webcast Transcript: All You Need to Know About the Use of Truvada to Prevent HIV Infection (Pre-Exposure Prophylaxis- PrEP)
TRANSCRIPT FROM GOOGLE HANGOUT ON HIV PRE-EXPOSURE PROPHYLAXIS
(PrEP) WITH DAMON JACOBS AND NELSON VERGEL
Scott: Hello everybody. Scott Sillary here with Viral Marketing. I'm here
with Nelson Vergel and Damon Jacobs. Welcome to the Power Hangout. It's going
to be fantastic. Nelson, tell us a little bit about what we're going to be
goingAnonymoushttp://www.blogger.com/profile/07508096149475469122noreply@blogger.comtag:blogger.com,1999:blog-7591606.post-59771629837936965442015-07-23T11:04:00.002-05:002015-07-23T11:04:32.257-05:00The HIV Prevention Pill: A Free Webcast on July 29, 6:30 PM (EDT)
The HIV Prevention Pill: A Free Webcast on July 29, 6:30 PM (EDT)
Activists and educators Damon Jacobs and Nelson Vergel will answer questions about the use of Truvada for HIV Pre-Exposure Prophylaxis (PrEP) covering research facts, misconceptions and access of this highly effective prevention tool. This webcast is of interest to the lay person and clinicians. Please RSVP by clicking "Yes" Anonymoushttp://www.blogger.com/profile/07508096149475469122noreply@blogger.comtag:blogger.com,1999:blog-7591606.post-70623334215449726162015-06-24T09:41:00.000-05:002015-06-24T09:41:14.065-05:00Impaired sperm motility in HIV-infected men: an unexpected adverse effect of efavirenz?
Impaired sperm motility in HIV-infected men: an unexpected adverse effect of efavirenz?
Frapsauce C, et al. Hum Reprod. 2015.
Authors
Frapsauce C1, Grabar S2, Leruez-Ville M3, Launay O4, Sogni P5, Gayet V6, Viard JP7, De Almeida M8, Jouannet P8, Dulioust E1.Author information
1Laboratoire de Biologie de la Reproduction, Hôpital Broca-Cochin-Hôtel Dieu, Assistance Publique-Hôpitaux de Anonymoushttp://www.blogger.com/profile/07508096149475469122noreply@blogger.comtag:blogger.com,1999:blog-7591606.post-57731211522567564592015-03-16T12:22:00.001-05:002015-03-16T12:22:26.879-05:00HIV Activist Raises Hope and Warnings in New Attachment Inhibitor Trial.
Video: HIV Activist Raises Hope and Warnings in New Attachment Inhibitor Trial.
Leading HIV activist Nelson Vergel raises hopes but also warns HIV salvage patients and their physicians about functional monotherapy risks in the Bristol-Meyers Squibb (BMS) new attachment inhibitor study (Fostemsavir, BMS-663068) currently enrolling (2015-2016). This innovative drug, along with Taimed's Anonymoushttp://www.blogger.com/profile/07508096149475469122noreply@blogger.comtag:blogger.com,1999:blog-7591606.post-29012498759896649122015-03-04T21:34:00.002-06:002015-03-04T21:35:38.283-06:00Starting HIV Medications Within First Weeks of Infection Decreases Hidden Virus
Clin Infect Dis. (2015) doi: 10.1093/cid/civ171First published online: March 3, 2015
Impact of the Earliness of Antiretroviral Therapy Initiation During Primary HIV-1 Infection on the Decay of Cell-Associated HIV-DNA
Moussa Laanani1,2,
1Inserm, CESP Centre for Research in Epidemiology and Population Health, U1018, Paris-Sud University, Le Anonymoushttp://www.blogger.com/profile/07508096149475469122noreply@blogger.comtag:blogger.com,1999:blog-7591606.post-53143799785493991782015-03-03T11:27:00.001-06:002015-03-03T11:35:30.488-06:00Most Important HIV Research Reports from CROI 2015
From Jules Levin: perhaps the biggest stories out of CROI from my perspective are the development of 2 new HIV therapies - the new attachment inhibitor & the new maturation inhibitors, as well as the safety & efficacy of TAF, and an important message out of CROI is that TAF can also be used in HCV coinfected patients as a replacement for TDF in Anonymoushttp://www.blogger.com/profile/07508096149475469122noreply@blogger.comtag:blogger.com,1999:blog-7591606.post-87307875357448308292015-01-30T09:07:00.001-06:002015-01-30T09:10:11.833-06:00Prezcobix and Evotaz: Two New HIV Fixed Dose Combinations Approved this Week
January 29, 2015
Janssen Therapeutics, Division of Janssen Products, LP (Janssen), today announced the U.S. Food and Drug Administration (FDA) has approved PREZCOBIX™ (darunavir 800 mg/cobicistat 150 mg) tablets, an HIV-1 protease inhibitor combined with a CYP3A4 inhibitor, for the treatment of human immunodeficiency virus (HIV-1) in combination with other antiretroviral agents for Anonymoushttp://www.blogger.com/profile/07508096149475469122noreply@blogger.comtag:blogger.com,1999:blog-7591606.post-72494678662155660482014-11-15T11:32:00.001-06:002014-11-15T11:32:45.098-06:00Cost Effectiveness of Current HIV Cure Approaches
Published: November 14, 2014
DOI: 10.1371/journal.pone.0113031
Abstract
Background
We examined efficacy, toxicity, relapse, cost, and quality-of-life thresholds of hypothetical HIV cure interventions that would make them cost-effective compared to life-long antiretroviral therapy (ART).
Methods
We used a computer simulation model to assess three HIV cure strategies: Gene Therapy, Anonymoushttp://www.blogger.com/profile/07508096149475469122noreply@blogger.comtag:blogger.com,1999:blog-7591606.post-81044549825091655842014-11-15T09:56:00.002-06:002014-11-15T09:56:26.171-06:00Groundbreaking HIV vaccine's effects were real – and could be made to work better
Findings from further studies using a reformulation of the only HIV vaccine that has ever worked in a large efficacy trial were presented at the recent HIV Research for Prevention conference (HIVR4P). They showed evidence of stronger antibody responses, and in-depth analysis of these responses shows that by further developing a similar vaccine it may be possible to push the immune system Anonymoushttp://www.blogger.com/profile/07508096149475469122noreply@blogger.comtag:blogger.com,1999:blog-7591606.post-59762674912671277392014-11-15T09:45:00.001-06:002014-11-15T09:54:33.073-06:00Prevalence and risk factors of sleep disturbances in a large HIV-infected adult population.
Prevalence and risk factors of sleep disturbances in a large HIV-infected adult population.
Authors
Allavena C1, Guimard T2, Billaud E3, de la Tullaye S4, Reliquet V1, Pineau S3, Hüe H3, Supiot C1,Chennebault JM5, Michau C6, Hitoto H7, Vatan R8, Raffi F1.
Author information
Journal
J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19576. doi: Anonymoushttp://www.blogger.com/profile/07508096149475469122noreply@blogger.comtag:blogger.com,1999:blog-7591606.post-23212939368766880012014-10-22T16:52:00.002-05:002014-10-22T16:52:34.710-05:00Ibalizumab: First HIV Drug to Get Orphan Drug Status for Salvage Patients
Shares of TaiMed Biologics Inc, which manufactures drugs to treat AIDS, soared 12.93 percent yesterday after its new TMB-355 drug for intravenous injection was granted orphan drug status in the US.
The company’s shares closed at NT$151.2 yesterday, outperforming the over-the-counter benchmark index, which ended up 0.56 percent.
The granting of orphan status could shorten the time it takes for Anonymoushttp://www.blogger.com/profile/07508096149475469122noreply@blogger.comtag:blogger.com,1999:blog-7591606.post-26578590408356535532014-10-19T17:01:00.000-05:002014-10-19T17:01:04.181-05:00Demystifying HIV Pre-Exposure Prophylaxis
Pre-Exposure
Prophylaxis or PrEP is an HIV prevention strategy where an HIV negative person
takes a daily pill to reduce their risk of contracting HIV. It's important to
note that PrEP is not the same as PEP or Post-Exposure Prophylaxis, which HIV
treatment given to individuals within 72 hours after exposure to HIV to prevent
infection from taking hold.
The only currently
approved Anonymoushttp://www.blogger.com/profile/07508096149475469122noreply@blogger.comtag:blogger.com,1999:blog-7591606.post-28470477800625543942014-10-17T23:57:00.003-05:002014-10-17T23:57:25.268-05:00Video: Three PrEP Myths Busted (One Pill Per Day to Prevent HIV)Anonymoushttp://www.blogger.com/profile/07508096149475469122noreply@blogger.comtag:blogger.com,1999:blog-7591606.post-49388643320722589402014-10-10T15:11:00.000-05:002014-10-10T15:11:49.294-05:00The U.S. Food and Drug Administration today approved Harvoni (ledipasvir and sofosbuvir) to treat chronic hepatitis C virus (HCV) genotype 1 infection.
For Immediate Release
October 10, 2014
Release
The U.S. Food and Drug Administration today approved Harvoni (ledipasvir and sofosbuvir) to treat chronic hepatitis C virus (HCV) genotype 1 infection.
Harvoni is the first combination pill approved to treat chronic HCV genotype 1 infection. It is also the first approved regimen that does not require administration with interferon or Anonymoushttp://www.blogger.com/profile/07508096149475469122noreply@blogger.comtag:blogger.com,1999:blog-7591606.post-74440938503280374202014-10-08T14:15:00.006-05:002014-10-08T14:15:52.285-05:00As PrEP Becomes More Available, Couples With One HIV + Partner Consider Treatment
It has been recommended that gay and bisexual men consider taking pre-exposure prophylaxis, or PrEP, for HIV prevention, but there is one demographic that, according to many health care professionals, is an ideal candidate for this treatment: HIV-negative men with HIV-positive male partners, relationships that are referred to as serodiscordant.
For many of these couples, PrEP may offer a Anonymoushttp://www.blogger.com/profile/07508096149475469122noreply@blogger.comtag:blogger.com,1999:blog-7591606.post-21982621151573733002014-10-08T14:12:00.000-05:002014-10-08T14:12:02.259-05:00What You Should Know About EbolaImportant facts summarized in this great figure.
Anonymoushttp://www.blogger.com/profile/07508096149475469122noreply@blogger.com